Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

New Bcl-2 Inhibitor Data At ASCO

 
• By Xu Hu
  
Apoptosis
Apoptosis-focused Ascentage also tapping into TPD area, where it hopes to progress a p53-MDM2 targeted asset into Phase I next year. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Therapy Areas